Platinum compounds, such as cisplatin, carboplatin, oxaliplatin and nedaplatin, are widely used to treat a number of solid malignancies. Nedaplatin is a second‑generation platinum complex, based on its pronounced anti-cancer activities against several solid tumors being equivalent to that of cisplatin, but with lower nephrotoxicity. In this context, the present study aimed to investigate the potential anti‑cancer effect by combining nedaplatin with ABT‑737. It was found that nedaplatin greatly increased ABT-737-mediated apoptosis in A549 and 95‑D cells, accompanied by enhanced cleavage of poly(ADP‑ribose) polymerase and caspase‑3. In addition, this enhancement was also paralleled by cytochrome c release and dissipation of mitochondrial membrane potential. Additional mechanistic investigations revealed that nedaplatin plus ABT‑737 exerted a synergistic effect on cancer cells through their ability to accelerate the degradation of Mcl‑1. The present study has revealed nedaplatin as a pertinent sensitizer to ABT‑737, which opens up new avenues for this promising BH3‑mimetic molecule in the clinic.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: